专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

FI20030140A0 未知
公开(公告)号：FI20030140A0
公开(公告)日：2003-01-30
申请号：FI20030140
申请日：2003-01-30
申请人： HELLMAN JUKKA , KAEKOENEN SANNA-MARIA , LOEVGREN TIMO , IVASKA KAISA , VAEAENAENEN KALERVO , PETTERSSON KIM
发明人： IVASKA KAISA , HELLMAN JUKKA , KAEKOENEN SANNA-MARIA , LOEVGREN TIMO , VAEAENAENEN KALERVO , PETTERSSON KIM
IPC分类号： C12Q20060101 , C12Q

2. 发明专利

FI973371A0 未知
公开(公告)号：FI973371A0
公开(公告)日：1997-08-15
申请号：FI973371
申请日：1997-08-15
申请人： HELLMAN JUKKA , KAEKOENEN SANNA MARIA , KARP MATTI , LOEVGREN TIMO , VAEAENAENEN H KALERVO , PETTERSSON KIM
发明人： HELLMAN JUKKA , KAEKOENEN SANNA-MARIA , KARP MATTI , LOEVGREN TIMO , VAEAENAENEN H KALERVO , PETTERSSON KIM
IPC分类号： G01N33/53 , C07K14/47 , C07K14/78 , C07K16/18 , C12N5/10 , C12N15/02 , C12P21/08 , G01N33/68 , C07K

3. 发明专利

FI990693A0 未知
公开(公告)号：FI990693A0
公开(公告)日：1999-03-29
申请号：FI990693
申请日：1999-03-29
申请人： KAEKOENEN SANNA MARIA , LUUKINEN HEIKKI , PETTERSSON KIM , LOEVGREN TIMO , VAEAENAENEN H KALERVO
发明人： KAEKOENEN SANNA-MARIA , LUUKINEN HEIKKI , PETTERSSON KIM , LOEVGREN TIMO , VAEAENAENEN H KALERVO
IPC分类号： G01N33/68
摘要： This invention concerns a method for the assessment of bone fragility and fracture risk, or osteoporosis, in a person. In said method, the concentration of gamma-carboxylated osteocalcin (COC) and optionally also the concentration of intact or total osteocalcin (IOC or TOC, respectively) in a body fluid sample of said person is measured. The concentration of gamma-carboxylated osteocalcin (COC) so obtained is compared to the mean concentration of gamma-carboxylated osteocalcin (mean COC) in similar body fluid samples of the population of the same age and sex. Alternatively, the determined ratio COC/IOC or COC/TOC for said person, is compared to the mean ratio COC/IOC or COC/TOC, (mean ratio COC/IOC or mean ratio COC/TOC) determined from measurements in similar body fluid samples of the population of the same age and sex. A measured COC that is lower than the mean COC is used as indication of osteoporosis, bone fragility or increased risk of bone fracture in said person. Preferably, a determined ratio COC/TOC that is lower than the mean ratio COC/TOC is used as indication of osteoporosis, bone fragility or increased risk of bone fracture in said person. The invention concerns further kits for use in the assessment according to this invention.

4. 发明专利

DE60041534D1 未知
公开(公告)号：DE60041534D1
公开(公告)日：2009-03-26
申请号：DE60041534
申请日：2000-03-20
申请人： KAEKONEN SANNA-MARIA , LOEVGREN TIMO , LUUKINEN HEIKKI , PETTERSSON KIM , VAEAENAENEN H KALERVO
发明人： KAEKONEN SANNA-MARIA , LUUKINEN HEIKKI , PETTERSSON KIM , LOEVGREN TIMO , VAEAENAENEN KALERVO H
IPC分类号： G01N33/68
摘要： This invention concerns a method for the assessment of bone fragility and fracture risk, or osteoporosis, in a person. In said method, the concentration of gamma-carboxylated osteocalcin (COC) and optionally also the concentration of intact or total osteocalcin (IOC or TOC, respectively) in a body fluid sample of said person is measured. The concentration of gamma-carboxylated osteocalcin (COC) so obtained is compared to the mean concentration of gamma-carboxylated osteocalcin (mean COC) in similar body fluid samples of the population of the same age and sex. Alternatively, the determined ratio COC/IOC or COC/TOC for said person, is compared to the mean ratio COC/IOC or COC/TOC, (mean ratio COC/IOC or mean ratio COC/TOC) determined from measurements in similar body fluid samples of the population of the same age and sex. A measured COC that is lower than the mean COC is used as indication of osteoporosis, bone fragility or increased risk of bone fracture in said person. Preferably, a determined ratio COC/TOC that is lower than the mean ratio COC/TOC is used as indication of osteoporosis, bone fragility or increased risk of bone fracture in said person. The invention concerns further kits for use in the assessment according to this invention.

5. 发明专利

AT422672T 未知
公开(公告)号：AT422672T
公开(公告)日：2009-02-15
申请号：AT00914195
申请日：2000-03-20
申请人： KAEKONEN SANNA-MARIA , LUUKINEN HEIKKI , PETTERSSON KIM , LOEVGREN TIMO , VAEAENAENEN H KALERVO
发明人： KAEKONEN SANNA-MARIA , LUUKINEN HEIKKI , PETTERSSON KIM , LOEVGREN TIMO , VAEAENAENEN H
IPC分类号： G01N33/68
摘要： This invention concerns a method for the assessment of bone fragility and fracture risk, or osteoporosis, in a person. In said method, the concentration of gamma-carboxylated osteocalcin (COC) and optionally also the concentration of intact or total osteocalcin (IOC or TOC, respectively) in a body fluid sample of said person is measured. The concentration of gamma-carboxylated osteocalcin (COC) so obtained is compared to the mean concentration of gamma-carboxylated osteocalcin (mean COC) in similar body fluid samples of the population of the same age and sex. Alternatively, the determined ratio COC/IOC or COC/TOC for said person, is compared to the mean ratio COC/IOC or COC/TOC, (mean ratio COC/IOC or mean ratio COC/TOC) determined from measurements in similar body fluid samples of the population of the same age and sex. A measured COC that is lower than the mean COC is used as indication of osteoporosis, bone fragility or increased risk of bone fracture in said person. Preferably, a determined ratio COC/TOC that is lower than the mean ratio COC/TOC is used as indication of osteoporosis, bone fragility or increased risk of bone fracture in said person. The invention concerns further kits for use in the assessment according to this invention.

6. 发明专利

ES2320848T3 PROCEDIMIENTO PARA LA PREDICCION DE FRACTURAS OSEAS MEDIANTE MEDICIONES DE OSTEOCALCINA. 未知
公开(公告)号：ES2320848T3
公开(公告)日：2009-05-29
申请号：ES00914195
申请日：2000-03-20
申请人： KAKONEN SANNA-MARIA , LUUKINEN HEIKKI , PETTERSSON KIM , LOVGREN TIMO , VAANANEN H KALERVO
发明人： KAKONEN SANNA-MARIA , LUUKINEN HEIKKI , PETTERSSON KIM , LOVGREN TIMO , VAANANEN H KALERVO
IPC分类号： G01N33/68
摘要： Procedimiento para la evaluación de la fragilidad ósea y el riesgo de fractura, o la osteoporosis, en una persona, que comprende las etapas siguientes a) medir la concentración de osteocalcina gamma-carboxilada (COC) por medio de por lo menos un anticuerpo monoclonal o policlonal o fragmento del mismo que es específico para la osteocalcina gammacarboxilada y siendo un anticuerpo o fragmento cuya especificidad para la osteocalcina gamma-carboxilada depende de la presencia de iones Ca 2+ , disminuyendo dicha especificidad en presencia de dichos iones Ca 2+ ; y también la concentración de osteocalcina intacta (IOC) u osteocalcina total (TOC) en una muestra de suero o de plasma de dicha persona, b) comparar la razón determinada COC/IOC o COC/TOC, para dicha persona con la razón media COC/IOC o la razón media COC/TOC, determinadas a partir de mediciones en unas muestras de fluidos corporales similares de la población del mismo sexo y edad, y c) utilizar la razón determinada COC/IOC o COC/TOC que es inferior a la razón media COC/IOC o la razón media COC/TOC como indicación de osteoporosis, fragilidad ósea o aumento del riesgo de fractura ósea en dicha persona.

7. 发明专利

FI20030652A0 未知
公开(公告)号：FI20030652A0
公开(公告)日：2003-04-30
申请号：FI20030652
申请日：2003-04-30
申请人： ERIKSSON SUSANN , PETTERSSON KIM
发明人： ERIKSSON SUSANN , PETTERSSON KIM
IPC分类号： G01N33/68

8. 发明申请

WO0244725A8 BIOANALYTICAL ASSAY 审中-公开
标题翻译：生物分析
公开(公告)号：WO0244725A8
公开(公告)日：2002-10-17
申请号：PCT/FI0101024
申请日：2001-11-26
申请人： INNOTRAC DIAGNOSTICS OY , PETTERSSON KIM
发明人： PETTERSSON KIM
IPC分类号： B82B1/00 , G01N33/53 , G01N33/543 , G01N33/545
CPC分类号： G01N33/54346 , Y10T428/2982
摘要： The present invention relates to a nanoparticle comprising a specific binding reactant, said nanoparticle being useful for determining an analyte to which analyte or complex comprising said analyte said binding reactant is specific. Characteristic for the nanoparticle is that the diameter of said nanoparticle is less than 200 nm, said nanoparticle is coated with multiple said specific binding reactants to the extent that the affinity constant of said nanoparticle towards said analyte essentially exceeds that of free said binding reactant towards said analyte and/or the association rate constant between said nanoparticle and said analyte essentially exceeds the association rate constant between free said binding reactant and said analyte; and said nanoparticle comprises a detectable feature. The invention also relates to biochemical assays using said nanoparticle. The assay further relates to a proximity based homogenous assay comprising a first group labeled with an energy donating compound (donor) and a second group labeled with an energy accepting compound (acceptor), wherein the donor is luminescent and has a long excited state lifetime and the acceptor is luminescent having a short or long excited state lifetime or the acceptor is non-luminescent, and the increase or decrease, respectively, in the energy transfer from the donor to the acceptor resulting from shortening or lengthening, respectively, of the distance between said groups, is measured. Characteristic for the assay is that the donor is a nanoparticle.
摘要翻译：本发明涉及包含特异性结合反应物的纳米颗粒，所述纳米颗粒可用于确定包含所述分析物的分析物或复合物的分析物，所述分析物所述结合反应物是特异性的。纳米颗粒的特征在于所述纳米颗粒的直径小于200nm，所述纳米颗粒用多种所述特异性结合反应物涂覆至所述纳米颗粒对所述分析物的亲和常数基本上超过所述游离的所述结合反应物对所述所述纳米颗粒与所述分析物之间的分析物和/或缔合速率常数基本上超过游离所述结合反应物与所述分析物之间的缔合速率常数; 并且所述纳米颗粒包含可检测特征。本发明还涉及使用所述纳米颗粒的生物化学测定。该测定还涉及基于接近度的均相测定法，其包含用供能化合物（供体）标记的第一组和用能量受体化合物（受体）标记的第二组，其中供体是发光的并且具有长激发态寿命和受主发光具有短的或长的激发态寿命或者受体不发光，并且分别在从供体到受体的能量转移中分别由缩短或延长所述组，是测量的。测定的特征是供体是纳米颗粒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式